{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:49:29Z","timestamp":1744213769333},"reference-count":45,"publisher":"Wiley","issue":"3-4","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":5418,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1992,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Verapamil has been shown to overcome acquired drug resistance to vincristine in P388 leukemia both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. To study the selectivity of this action, the effect of addition of verapamil on the cytotoxicity of vincristine was studied using lymphocytes from eight patients with chronic lymphocytic leukemia (CLL). lymphoblasts from a T\u2010acute lymphoblastic leukemia (T\u2010ALL) cell line (GM 3639), and peripheral blood lymphocytes (PBL) from eight normal healthy volunteers. Using the differential staining cytotoxicity (DiSC) assay, we demonstrated that verapamil at 1 \u03bc<jats:sc>m<\/jats:sc> concentration potentiated the <jats:italic>in\u2010vitro<\/jats:italic> cytotoxicity of vincristine on CLL and GM 3639 cells in concentrations of 0\u00b704\u20130\u00b725 \u03bcg\/l. There was however, no enhancement of cytotoxicity noted against the control PBL. The data demonstrate that verapamil preferentially enhances the <jats:italic>in\u2010vitro<\/jats:italic> cytotoxicity of vincristine on CLL and GM 3639 cells but no enhancement of cytotoxicity is seen against PBL.<\/jats:p>","DOI":"10.1002\/hon.2900100314","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T17:58:38Z","timestamp":1171907918000},"page":"225-231","source":"Crossref","is-referenced-by-count":2,"title":["Verapamil preferentially potentiates <i>in\u2010vitro<\/i> cytotoxicity of vincristine on malignant lymphoid cells"],"prefix":"10.1002","volume":"10","author":[{"given":"Imtiaz A.","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas V.","family":"Costea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"222","article-title":"Genetic instability in the development of drug resistance","volume":"12","author":"Goldie J. H.","year":"1985","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_3_2","first-page":"1967","article-title":"Overcoming of vincristine resistance in P 388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine by verapamil","volume":"41","author":"Tsuruo T.","year":"1981","journal-title":"Cancer Res."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(82)90097-1"},{"key":"e_1_2_1_5_2","first-page":"2905","article-title":"Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers","volume":"43","author":"Tsuruo T.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_6_2","first-page":"4730","article-title":"Increased accumulation of vincristine and adriamycin in drug resistant P 388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors","volume":"42","author":"Tsuruo T.","year":"1982","journal-title":"Cancer Res."},{"key":"e_1_2_1_7_2","first-page":"6365","article-title":"Verapamil reversal of doxorubicin resistance in multi\u2010drug resistance human myeloma cells and association with drug accumulation and DNA damage","volume":"48","author":"Bellamy W. T.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_8_2","first-page":"778","article-title":"Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemia cells by verapamil","volume":"46","author":"Beck W. T.","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_1_9_2","first-page":"3696","article-title":"Enhancement of sensitivity to adriamycin resistant P 388 leukemia by calmodulin inhibitor trifluoperazine","volume":"43","author":"Ganapathi R.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6203171"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112450"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.4"},{"key":"e_1_2_1_13_2","first-page":"258","article-title":"Comparison of dye exclusion assay with a clonogenic assay in the determination of drug\u2010induced cytotoxicity","volume":"43","author":"Weisenthal L. M.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_14_2","first-page":"749","article-title":"A novel dye exclusion method for testing in\u2010vitro chemosensitivity of human tumors","volume":"43","author":"Weisenthal L. M.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830415)51:8<1490::AID-CNCR2820510823>3.0.CO;2-O"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880315)61:6<1104::AID-CNCR2820610609>3.0.CO;2-6"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06323.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican0389-44"},{"key":"e_1_2_1_19_2","first-page":"907","article-title":"Multi\u2010drug resistance: P\u2010glycoprotein and its allies\u2014the elusive foes","volume":"8","author":"Chabner B. A.","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.1.265"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.9.696"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V73.3.747.747","article-title":"Immunohistochemical detection and quantitation of P\u2010glycoprotein in multiple drug\u2010resistant human myeloma cells: Association with level of drug resistance and drug accumulation","volume":"74","author":"Dalton W. S.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/316820a0"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91969-6"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.bi.58.070189.001033","article-title":"The biochemistry of P\u2010glycoprotein mediated multi\u2010drug resistance","volume":"58","author":"Endicott J. A.","year":"1989","journal-title":"Annu. Rev. Biochem."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(90)90028-R"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.21.7735"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90141-K"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)90869-O"},{"key":"e_1_2_1_30_2","first-page":"271","article-title":"Activation of protein kinase C (PKC) increases vincristine efflux and resistance in drug\u2010sensitive MCF\u20107 cells","volume":"27","author":"Fine R. L.","year":"1986","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1016\/S0021-9258(18)43501-6","article-title":"Inhibitory action of chlorpromazine, dibucaine, and other phospholipid\u2010interacting drugs on calcium activated, phospholipid dependent protein kinase","volume":"255","author":"Mori T.","year":"1980","journal-title":"J. Biol. Chem."},{"issue":"3","key":"e_1_2_1_32_2","first-page":"428","article-title":"Chronic lymphatic leukemia cells have increased protein kinase C activity as compared to normal peripheral blood lymphocytes","volume":"35","author":"Malik I.","year":"1987","journal-title":"Clin. Res."},{"issue":"5","key":"e_1_2_1_33_2","first-page":"214","article-title":"Chronic lymphocytic leukemia (CLL) cells have increased membrane fluidity","volume":"72","author":"Malik I.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_34_2","first-page":"3959","article-title":"Mechanism of multi\u2010drug resistance in HL60 cells: Evidence that a surface membrane protein distinct from P\u2010glycoprotein contributes to reduced cellular accumulation of drug","volume":"48","author":"McGrath T.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(90)90011-4"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(90)90010-D"},{"key":"e_1_2_1_37_2","first-page":"104","article-title":"Molecular mechanisms of resistance in sensitive and resistant cell lines","volume":"11","author":"Gieseler F.","year":"1992","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_1_38_2","first-page":"40","article-title":"Verapamil does not enhance anti cancer drug toxicity for human marrow myeloid\u2010macrophage colony forming unites (CFU\u2010GM)","volume":"3","author":"Fine R. L.","year":"1984","journal-title":"Proc. Am. Assoc. Clin. Oncol."},{"key":"e_1_2_1_39_2","first-page":"2330","article-title":"Combination therapy of vinca alkaloids and nicardipine in patients with non\u2010Hodgkin's lymphoma who became resistant to various chemotherapeutic agents and relapsed","volume":"10","author":"Honda T.","year":"1983","journal-title":"Jpn. J. Cancer Chemother."},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198608000-00016"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.4.641"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.880"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.415"},{"key":"e_1_2_1_44_2","first-page":"57","article-title":"Infusional vinblastine with multi\u2010drug resistance reversers verapamil and chloroquine in metastatic breast cancer","volume":"10","author":"Lower E. E.","year":"1991","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"1","key":"e_1_2_1_45_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.1991.9.1.17","article-title":"P\u2010glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high\u2010dose verapamil","volume":"9","author":"Miller T. P.","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_1_46_2","first-page":"124","article-title":"Phase I clinical trial of R\u2010verapamil in drug resistant malignant disease","volume":"11","author":"Schumacher K.","year":"1992","journal-title":"Proc. Am. Soc. Clin. Oncol."}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900100314","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900100314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T21:35:53Z","timestamp":1693604153000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900100314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,5]]},"references-count":45,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[1992,5]]}},"alternative-id":["10.1002\/hon.2900100314"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900100314","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,5]]}}}